Estuary Biotherapeutics · Series A
Charting a new course for patients with kidney disease by developing targeted gene therapies for ADPKD.
Amount
$93M
Round
Series A
Valuation
—
Announced
Oct 2026
Investors
Lead investor
RA Capital ManagementNotes
auto-discovered via firecrawl
Other Estuary Biotherapeutics rounds
| Date | Round | Amount | |
|---|---|---|---|
| Oct 2026 | Seed | $10M | Details → |